NCT00050622

Brief Summary

The purpose of this study is to determine the effectiveness of behavioral treatment, drug treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder (ADHD). This study will also examine the interactions between different levels of behavioral and drug treatments.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
154

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2001

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2001

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

December 16, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 17, 2002

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2004

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2005

Completed
11.3 years until next milestone

Results Posted

Study results publicly available

September 30, 2016

Completed
Last Updated

September 30, 2016

Status Verified

August 1, 2016

Enrollment Period

2.9 years

First QC Date

December 16, 2002

Results QC Date

May 31, 2016

Last Update Submit

August 8, 2016

Conditions

Outcome Measures

Primary Outcomes (2)

  • Social Behavior-Negative Verbalizations

    Sum of daily frequency of Verbal Abuse toward staff members, Teasing toward peers, and Cursing/Swearing as defined by a behavioral point system that doubles as an objective measure of children's behavior. All instances of these behaviors were reported and noted as they occur throughout daily activities.

    Daily for 45 days

  • Classroom Behavior

    Daily records of percentage of assigned problems completed by children in a 60-minute classroom period.

    Daily for 45 days

Secondary Outcomes (1)

  • Treatment Satisfaction

    End of Treatment

Study Arms (12)

No Treatment

PLACEBO COMPARATOR

No Medication, No Behavior Modification (BMOD)

Drug: Placebo

Low Dose Medication Only

ACTIVE COMPARATOR

0.15 mg/kg methylphenidate (MPH), No BMOD

Drug: Methylphenidate 0.15 mg/kg

Medium Dose Medication Only

ACTIVE COMPARATOR

0.3 mg/kg MPH, No BMOD

Drug: Methylphenidate 0.3 mg/kg

Higher Dose Medication Only

ACTIVE COMPARATOR

0.6 mg/kg MPH, No BMOD

Drug: Methylphenidate 0.6 mg/kg

Low Intensity BMOD Only

ACTIVE COMPARATOR

Placebo, Low Intensity BMOD

Behavioral: Low-Intensity BMODDrug: Placebo

Low Intensity BMOD + Low Dose Medication

ACTIVE COMPARATOR

0.15 mg/kg MPH, Low Intensity BMOD

Drug: Methylphenidate 0.15 mg/kgBehavioral: Low-Intensity BMOD

Low Intensity BMOD + Medium Dose Medication

ACTIVE COMPARATOR

0.3 mg/kg MPH, Low Intensity BMOD

Behavioral: Low-Intensity BMODDrug: Methylphenidate 0.3 mg/kg

Low Intensity BMOD + Higher Dose Medication

ACTIVE COMPARATOR

0.6 mg/kg MPH, Low Intensity BMOD

Behavioral: Low-Intensity BMODDrug: Methylphenidate 0.6 mg/kg

High Intensity BMOD Only

ACTIVE COMPARATOR

Placebo, High Intensity BMOD

Behavioral: High Intensity BMOD

High Intensity BMOD + Low Dose Medication

ACTIVE COMPARATOR

0.15 mg/kg MPH, High Intensity BMOD

Drug: Methylphenidate 0.15 mg/kgBehavioral: High Intensity BMOD

High Intensity BMOD + Medium Dose Medication

ACTIVE COMPARATOR

0.3 mg/kg MPH, High Intensity BMOD

Drug: Methylphenidate 0.3 mg/kgBehavioral: High Intensity BMOD

High Intensity BMOD + Higher Dose Medication

ACTIVE COMPARATOR

0.6 mg/kg MPH, High Intensity BMOD

Drug: Methylphenidate 0.6 mg/kgBehavioral: High Intensity BMOD

Interventions

0.15 m/kg/dose immediate-release methylphenidate

High Intensity BMOD + Low Dose MedicationLow Dose Medication OnlyLow Intensity BMOD + Low Dose Medication

Lower-intensity behavioral treatment package.

Low Intensity BMOD + Higher Dose MedicationLow Intensity BMOD + Low Dose MedicationLow Intensity BMOD + Medium Dose MedicationLow Intensity BMOD Only

0.3 mg/kg/dose immediate-release methylphenidate

High Intensity BMOD + Medium Dose MedicationLow Intensity BMOD + Medium Dose MedicationMedium Dose Medication Only
Low Intensity BMOD OnlyNo Treatment

0.3 mg/kg/dose immediate-release methylphenidate

High Intensity BMOD + Higher Dose MedicationHigher Dose Medication OnlyLow Intensity BMOD + Higher Dose Medication

Comprehensive high-intensity Summer Treatment Program (STP)

High Intensity BMOD + Higher Dose MedicationHigh Intensity BMOD + Low Dose MedicationHigh Intensity BMOD + Medium Dose MedicationHigh Intensity BMOD Only

Eligibility Criteria

Age5 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Attention Deficit Hyperactivity Disorder
  • IQ \>= 80

You may not qualify if:

  • History of seizures or other neurological problems
  • Medical history that would involve considerable risk in taking stimulant medication
  • History or concurrent diagnosis of any of the following disorders: pervasive developmental disorder, schizophrenia or other psychotic disorders, sexual disorder, organic mental disorder, or eating disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Florida International University Center for Children and Families

Miami, Florida, 33199, United States

Location

Center for Children and Families, University at Buffalo

Buffalo, New York, 14214, United States

Location

Related Publications (2)

  • Fabiano, G.A., Pelham, W.E., Gnagy, E.M., Wymbs, B.T., Chacko, A., Coles, E.K., Walker, K.S., Arnold, F., Burrows-MacLean, L., Massetti, G.M., & Hoffman, M.T. (2007). The single and combined effects of multiple intensities of behavior modification and multiple intensities of methylphenidate in a classroom setting. School Psychology Review, 36(2), 195-216.

    BACKGROUND
  • Pelham WE, Burrows-MacLean L, Gnagy EM, Fabiano GA, Coles EK, Wymbs BT, Chacko A, Walker KS, Wymbs F, Garefino A, Hoffman MT, Waxmonsky JG, Waschbusch DA. A dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD. J Abnorm Child Psychol. 2014 Aug;42(6):1019-31. doi: 10.1007/s10802-013-9843-8.

    PMID: 24429997BACKGROUND

Related Links

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Interventions

Methylphenidate

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PhenylacetatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Limitations and Caveats

Highly structured environment and direct observational measures were used. Additional study in natural school and home settings will be necessary.

Results Point of Contact

Title
William E. Pelham, Jr.
Organization
Florida International University

Study Officials

  • William E Pelham, PhD

    Professor, Florida International University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 16, 2002

First Posted

December 17, 2002

Study Start

September 1, 2001

Primary Completion

August 1, 2004

Study Completion

June 1, 2005

Last Updated

September 30, 2016

Results First Posted

September 30, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will share

Locations